Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non Operating Income (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Non Operating Income over the past 10 years, most recently at $2.4 million for Q4 2025.

  • Quarterly results put Non Operating Income at $2.4 million for Q4 2025, down 69.1% from a year ago — trailing twelve months through Dec 2025 was $20.8 million (down 28.51% YoY), and the annual figure for FY2025 was $20.8 million, down 28.51%.
  • Non Operating Income for Q4 2025 was $2.4 million at Viridian Therapeutics, Inc.\DE, down from $5.4 million in the prior quarter.
  • Over the last five years, Non Operating Income for VRDN hit a ceiling of $7.7 million in Q4 2024 and a floor of $34000.0 in Q2 2021.
  • Median Non Operating Income over the past 5 years was $3.9 million (2023), compared with a mean of $3.6 million.
  • Biggest five-year swings in Non Operating Income: soared 5669.86% in 2023 and later plummeted 69.1% in 2025.
  • Viridian Therapeutics, Inc.\DE's Non Operating Income stood at $135000.0 in 2021, then soared by 2330.37% to $3.3 million in 2022, then skyrocketed by 40.75% to $4.6 million in 2023, then surged by 67.76% to $7.7 million in 2024, then plummeted by 69.1% to $2.4 million in 2025.
  • The last three reported values for Non Operating Income were $2.4 million (Q4 2025), $5.4 million (Q3 2025), and $6.0 million (Q2 2025) per Business Quant data.